Parthak Prodhan
Concepts (437)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Extracorporeal Membrane Oxygenation | 32 | 2021 | 295 | 7.060 |
Why?
| Hypoplastic Left Heart Syndrome | 5 | 2018 | 98 | 2.530 |
Why?
| Infant | 57 | 2024 | 3733 | 2.360 |
Why?
| Infant, Newborn | 49 | 2024 | 2867 | 2.270 |
Why?
| Hospital Mortality | 18 | 2024 | 435 | 2.250 |
Why?
| Norwood Procedures | 5 | 2022 | 60 | 2.160 |
Why?
| Heart Defects, Congenital | 10 | 2024 | 619 | 2.060 |
Why?
| Heart-Assist Devices | 8 | 2016 | 163 | 1.880 |
Why?
| Child, Preschool | 48 | 2024 | 4076 | 1.800 |
Why?
| Palliative Care | 6 | 2020 | 214 | 1.760 |
Why?
| Respiration, Artificial | 8 | 2015 | 308 | 1.720 |
Why?
| Retrospective Studies | 51 | 2024 | 6607 | 1.700 |
Why?
| Heart Diseases | 7 | 2021 | 216 | 1.630 |
Why?
| Child | 54 | 2024 | 7248 | 1.490 |
Why?
| Hemolytic-Uremic Syndrome | 2 | 2021 | 15 | 1.410 |
Why?
| Length of Stay | 12 | 2024 | 663 | 1.400 |
Why?
| Heart Failure | 6 | 2022 | 565 | 1.370 |
Why?
| Cardiopulmonary Resuscitation | 5 | 2019 | 140 | 1.350 |
Why?
| Intensive Care Units, Pediatric | 10 | 2024 | 179 | 1.290 |
Why?
| Male | 67 | 2024 | 26761 | 1.280 |
Why?
| Tetralogy of Fallot | 7 | 2021 | 86 | 1.250 |
Why?
| Humans | 102 | 2024 | 52483 | 1.230 |
Why?
| Heart Transplantation | 9 | 2018 | 367 | 1.220 |
Why?
| Female | 69 | 2024 | 28171 | 1.200 |
Why?
| Registries | 10 | 2019 | 581 | 1.110 |
Why?
| Terminal Care | 2 | 2020 | 48 | 1.020 |
Why?
| Risk Factors | 21 | 2024 | 3889 | 1.020 |
Why?
| Cardiac Surgical Procedures | 9 | 2022 | 321 | 1.000 |
Why?
| Adolescent | 29 | 2021 | 6739 | 0.960 |
Why?
| Heart Arrest | 5 | 2024 | 158 | 0.880 |
Why?
| Cohort Studies | 11 | 2024 | 1542 | 0.870 |
Why?
| Down Syndrome | 4 | 2021 | 93 | 0.850 |
Why?
| Treatment Outcome | 23 | 2021 | 5422 | 0.760 |
Why?
| Adenovirus Infections, Human | 3 | 2024 | 7 | 0.760 |
Why?
| Systemic Inflammatory Response Syndrome | 3 | 2021 | 67 | 0.740 |
Why?
| Respiratory Insufficiency | 3 | 2014 | 120 | 0.730 |
Why?
| Pulmonary Artery | 1 | 2022 | 150 | 0.710 |
Why?
| Hospitalization | 9 | 2024 | 736 | 0.700 |
Why?
| Brain Diseases | 1 | 2021 | 79 | 0.670 |
Why?
| Hospice Care | 1 | 2020 | 26 | 0.660 |
Why?
| Patient Transfer | 5 | 2015 | 99 | 0.650 |
Why?
| Monitoring, Physiologic | 3 | 2016 | 122 | 0.650 |
Why?
| Gastrostomy | 3 | 2020 | 58 | 0.650 |
Why?
| American Heart Association | 1 | 2019 | 32 | 0.650 |
Why?
| Critical Care | 5 | 2020 | 222 | 0.650 |
Why?
| Respiratory Distress Syndrome, Newborn | 2 | 2014 | 52 | 0.640 |
Why?
| Critical Illness | 7 | 2022 | 317 | 0.630 |
Why?
| Home Care Services | 1 | 2020 | 72 | 0.620 |
Why?
| Cardiopulmonary Bypass | 5 | 2013 | 95 | 0.620 |
Why?
| Respiratory Syncytial Virus Infections | 2 | 2010 | 42 | 0.620 |
Why?
| Follow-Up Studies | 10 | 2018 | 2279 | 0.600 |
Why?
| Oxygen | 3 | 2014 | 336 | 0.590 |
Why?
| Tracheostomy | 3 | 2020 | 76 | 0.570 |
Why?
| Enteral Nutrition | 2 | 2018 | 154 | 0.570 |
Why?
| Enterocolitis, Necrotizing | 1 | 2018 | 38 | 0.560 |
Why?
| Chromosome Disorders | 1 | 2017 | 32 | 0.550 |
Why?
| Time Factors | 14 | 2021 | 2968 | 0.550 |
Why?
| Heart Bypass, Right | 1 | 2017 | 15 | 0.540 |
Why?
| Patient Discharge | 4 | 2013 | 330 | 0.510 |
Why?
| Pressure | 1 | 2016 | 104 | 0.490 |
Why?
| Adrenal Cortex Hormones | 2 | 2015 | 116 | 0.490 |
Why?
| Airway Extubation | 2 | 2012 | 30 | 0.480 |
Why?
| Shock, Septic | 3 | 2011 | 82 | 0.480 |
Why?
| Chromosomes, Human, Pair 22 | 1 | 2015 | 39 | 0.470 |
Why?
| Transportation of Patients | 2 | 2012 | 38 | 0.470 |
Why?
| Acute-Phase Proteins | 1 | 2015 | 24 | 0.470 |
Why?
| Stenotrophomonas maltophilia | 1 | 2014 | 7 | 0.460 |
Why?
| Databases, Factual | 5 | 2018 | 706 | 0.450 |
Why?
| Gram-Negative Bacterial Infections | 1 | 2014 | 44 | 0.450 |
Why?
| Chromosome Deletion | 1 | 2015 | 142 | 0.450 |
Why?
| von Willebrand Factor | 1 | 2014 | 44 | 0.440 |
Why?
| von Willebrand Diseases | 1 | 2014 | 25 | 0.440 |
Why?
| Intensive Care Units, Neonatal | 2 | 2012 | 135 | 0.440 |
Why?
| Respiratory Tract Fistula | 1 | 2013 | 2 | 0.440 |
Why?
| Postoperative Hemorrhage | 1 | 2014 | 54 | 0.430 |
Why?
| Bronchial Fistula | 1 | 2013 | 5 | 0.430 |
Why?
| Phosphodiesterase 5 Inhibitors | 1 | 2013 | 7 | 0.430 |
Why?
| Sulfones | 1 | 2013 | 25 | 0.430 |
Why?
| Pleural Diseases | 1 | 2013 | 11 | 0.430 |
Why?
| Catheters | 2 | 2013 | 36 | 0.430 |
Why?
| Off-Label Use | 1 | 2013 | 24 | 0.430 |
Why?
| Oxygen Consumption | 2 | 2012 | 198 | 0.420 |
Why?
| Drug Utilization | 1 | 2013 | 78 | 0.420 |
Why?
| Survival Rate | 6 | 2018 | 945 | 0.420 |
Why?
| Cause of Death | 1 | 2014 | 160 | 0.410 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2013 | 19 | 0.410 |
Why?
| Pneumothorax | 1 | 2013 | 20 | 0.400 |
Why?
| Air Ambulances | 2 | 2012 | 23 | 0.400 |
Why?
| Piperazines | 1 | 2013 | 118 | 0.400 |
Why?
| Coronary Care Units | 1 | 2012 | 9 | 0.390 |
Why?
| Hemodynamics | 2 | 2011 | 263 | 0.390 |
Why?
| Positive-Pressure Respiration | 1 | 2013 | 61 | 0.390 |
Why?
| Altitude | 1 | 2012 | 16 | 0.390 |
Why?
| Intra-Abdominal Hypertension | 1 | 2012 | 6 | 0.390 |
Why?
| Hepacivirus | 1 | 2013 | 106 | 0.390 |
Why?
| Femoral Vein | 1 | 2012 | 38 | 0.380 |
Why?
| Postoperative Complications | 5 | 2022 | 1068 | 0.380 |
Why?
| Jugular Veins | 1 | 2012 | 34 | 0.380 |
Why?
| Renal Artery | 1 | 2012 | 32 | 0.380 |
Why?
| Carotid Arteries | 1 | 2012 | 77 | 0.380 |
Why?
| Sepsis | 2 | 2018 | 239 | 0.380 |
Why?
| Hepatitis C, Chronic | 1 | 2013 | 86 | 0.380 |
Why?
| Renal Circulation | 1 | 2012 | 56 | 0.380 |
Why?
| Hypertension, Pulmonary | 1 | 2013 | 130 | 0.380 |
Why?
| Heart Block | 1 | 2012 | 26 | 0.380 |
Why?
| Career Choice | 1 | 2013 | 116 | 0.380 |
Why?
| Emergencies | 1 | 2012 | 81 | 0.380 |
Why?
| Continuity of Patient Care | 1 | 2012 | 53 | 0.370 |
Why?
| Echocardiography, Doppler | 1 | 2012 | 57 | 0.370 |
Why?
| Echocardiography, Transesophageal | 1 | 2012 | 60 | 0.370 |
Why?
| Radiography, Thoracic | 3 | 2011 | 67 | 0.370 |
Why?
| Neutropenia | 1 | 2012 | 115 | 0.370 |
Why?
| Abnormalities, Multiple | 1 | 2013 | 166 | 0.370 |
Why?
| Femoral Artery | 1 | 2012 | 103 | 0.360 |
Why?
| Kidney Failure, Chronic | 1 | 2013 | 210 | 0.360 |
Why?
| Arrhythmias, Cardiac | 1 | 2012 | 96 | 0.360 |
Why?
| DiGeorge Syndrome | 2 | 2021 | 19 | 0.360 |
Why?
| Arkansas | 8 | 2012 | 2028 | 0.360 |
Why?
| Intensive Care Units | 4 | 2014 | 243 | 0.350 |
Why?
| Quality of Health Care | 1 | 2012 | 187 | 0.350 |
Why?
| Adrenal Insufficiency | 1 | 2010 | 18 | 0.340 |
Why?
| Survival Analysis | 5 | 2017 | 673 | 0.340 |
Why?
| Herpesviridae Infections | 1 | 2010 | 57 | 0.340 |
Why?
| Young Adult | 9 | 2017 | 4329 | 0.320 |
Why?
| Pulmonary Atelectasis | 1 | 2009 | 12 | 0.320 |
Why?
| Expectorants | 1 | 2009 | 14 | 0.320 |
Why?
| Respiratory Sounds | 2 | 2011 | 50 | 0.320 |
Why?
| Blood Specimen Collection | 1 | 2009 | 35 | 0.320 |
Why?
| Troponin I | 1 | 2009 | 18 | 0.320 |
Why?
| Deoxyribonucleases | 1 | 2009 | 23 | 0.310 |
Why?
| Wounds and Injuries | 1 | 2012 | 309 | 0.310 |
Why?
| Thoracic Injuries | 2 | 2013 | 36 | 0.310 |
Why?
| Diagnostic Techniques, Respiratory System | 1 | 2008 | 1 | 0.310 |
Why?
| Cardiac Catheterization | 4 | 2019 | 232 | 0.300 |
Why?
| Therapy, Computer-Assisted | 1 | 2008 | 31 | 0.300 |
Why?
| Kidney | 1 | 2013 | 707 | 0.300 |
Why?
| Prospective Studies | 7 | 2022 | 2481 | 0.300 |
Why?
| Acute Kidney Injury | 1 | 2012 | 319 | 0.300 |
Why?
| Anti-Bacterial Agents | 1 | 2014 | 807 | 0.300 |
Why?
| Altitude Sickness | 2 | 2012 | 8 | 0.300 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2008 | 46 | 0.300 |
Why?
| Respiratory Therapy | 1 | 2008 | 36 | 0.290 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2008 | 107 | 0.290 |
Why?
| Nurses | 1 | 2008 | 55 | 0.290 |
Why?
| Risk Assessment | 5 | 2017 | 1327 | 0.280 |
Why?
| Compartment Syndromes | 2 | 2007 | 17 | 0.280 |
Why?
| Internship and Residency | 1 | 2013 | 448 | 0.280 |
Why?
| Decision Making | 1 | 2010 | 282 | 0.280 |
Why?
| Lung | 4 | 2022 | 509 | 0.270 |
Why?
| Prognosis | 5 | 2012 | 2099 | 0.260 |
Why?
| Hospitals, Pediatric | 5 | 2015 | 243 | 0.250 |
Why?
| Case-Control Studies | 4 | 2019 | 1201 | 0.240 |
Why?
| Brain | 3 | 2012 | 1323 | 0.240 |
Why?
| Physicians | 1 | 2008 | 241 | 0.240 |
Why?
| Noninvasive Ventilation | 2 | 2017 | 22 | 0.230 |
Why?
| United States | 6 | 2019 | 5192 | 0.230 |
Why?
| Incidence | 4 | 2024 | 1062 | 0.230 |
Why?
| Heparin | 3 | 2014 | 88 | 0.230 |
Why?
| Algorithms | 1 | 2008 | 672 | 0.230 |
Why?
| Schistosomiasis haematobia | 1 | 2004 | 3 | 0.220 |
Why?
| Mitral Valve Insufficiency | 2 | 2015 | 52 | 0.220 |
Why?
| Urinary Bladder Diseases | 1 | 2004 | 18 | 0.220 |
Why?
| Hematuria | 1 | 2004 | 26 | 0.220 |
Why?
| Logistic Models | 5 | 2021 | 925 | 0.220 |
Why?
| Odds Ratio | 4 | 2021 | 558 | 0.220 |
Why?
| Chylothorax | 2 | 2022 | 16 | 0.220 |
Why?
| Kaplan-Meier Estimate | 3 | 2019 | 483 | 0.220 |
Why?
| Severity of Illness Index | 5 | 2021 | 1026 | 0.210 |
Why?
| Retinal Hemorrhage | 1 | 2003 | 13 | 0.210 |
Why?
| Asphyxia | 1 | 2003 | 8 | 0.210 |
Why?
| Orbital Diseases | 1 | 2003 | 12 | 0.210 |
Why?
| Encephalocele | 1 | 2003 | 11 | 0.210 |
Why?
| Neck Injuries | 1 | 2003 | 21 | 0.210 |
Why?
| Syndrome | 2 | 2015 | 247 | 0.210 |
Why?
| ROC Curve | 4 | 2012 | 253 | 0.210 |
Why?
| Water-Electrolyte Imbalance | 1 | 2022 | 16 | 0.200 |
Why?
| Pulmonary Edema | 1 | 2002 | 15 | 0.200 |
Why?
| Accidents, Traffic | 1 | 2003 | 90 | 0.200 |
Why?
| Anticoagulants | 3 | 2014 | 270 | 0.200 |
Why?
| Pilot Projects | 3 | 2014 | 721 | 0.200 |
Why?
| Quality Improvement | 1 | 2024 | 226 | 0.190 |
Why?
| Reoperation | 3 | 2014 | 465 | 0.190 |
Why?
| Program Evaluation | 3 | 2018 | 353 | 0.190 |
Why?
| Pediatrics | 2 | 2008 | 293 | 0.190 |
Why?
| Neoplasms | 1 | 2012 | 1325 | 0.190 |
Why?
| Reproducibility of Results | 3 | 2010 | 1229 | 0.180 |
Why?
| Delivery of Health Care | 1 | 2004 | 323 | 0.180 |
Why?
| Hypoxia, Brain | 1 | 2021 | 13 | 0.180 |
Why?
| Body Weight | 2 | 2014 | 523 | 0.180 |
Why?
| Health Information Systems | 1 | 2021 | 16 | 0.180 |
Why?
| Cerebrovascular Circulation | 3 | 2014 | 128 | 0.180 |
Why?
| North America | 1 | 2021 | 73 | 0.180 |
Why?
| Cerebral Infarction | 1 | 2021 | 34 | 0.180 |
Why?
| Gestational Age | 2 | 2013 | 417 | 0.180 |
Why?
| Pneumonia, Viral | 1 | 2024 | 178 | 0.180 |
Why?
| Heart Septal Defects, Atrial | 2 | 2012 | 45 | 0.170 |
Why?
| Aortic Coarctation | 1 | 2021 | 31 | 0.170 |
Why?
| Confidence Intervals | 1 | 2021 | 158 | 0.170 |
Why?
| Brain Edema | 1 | 2021 | 36 | 0.170 |
Why?
| Terminally Ill | 1 | 2020 | 13 | 0.170 |
Why?
| Catheter-Related Infections | 1 | 2020 | 49 | 0.170 |
Why?
| Central Venous Catheters | 1 | 2020 | 27 | 0.170 |
Why?
| Postoperative Period | 5 | 2022 | 170 | 0.170 |
Why?
| Cerebral Hemorrhage | 1 | 2021 | 97 | 0.170 |
Why?
| Spectroscopy, Near-Infrared | 4 | 2014 | 53 | 0.170 |
Why?
| Predictive Value of Tests | 3 | 2012 | 944 | 0.160 |
Why?
| Catheterization, Central Venous | 1 | 2020 | 84 | 0.160 |
Why?
| Platelet Membrane Glycoproteins | 1 | 2018 | 22 | 0.150 |
Why?
| Cell-Derived Microparticles | 1 | 2018 | 20 | 0.150 |
Why?
| Smoking | 1 | 2002 | 520 | 0.150 |
Why?
| C-Reactive Protein | 3 | 2015 | 155 | 0.150 |
Why?
| Haplotypes | 1 | 2018 | 92 | 0.150 |
Why?
| Aged, 80 and over | 3 | 2017 | 3392 | 0.140 |
Why?
| Infant Mortality | 1 | 2018 | 61 | 0.140 |
Why?
| Birth Weight | 1 | 2018 | 125 | 0.140 |
Why?
| Perioperative Care | 1 | 2017 | 43 | 0.140 |
Why?
| Academic Medical Centers | 1 | 2018 | 151 | 0.140 |
Why?
| Faculty, Medical | 1 | 2018 | 91 | 0.140 |
Why?
| Hospitals | 3 | 2022 | 182 | 0.140 |
Why?
| Shock, Cardiogenic | 1 | 2017 | 30 | 0.130 |
Why?
| Whole Blood Coagulation Time | 2 | 2014 | 6 | 0.130 |
Why?
| Waiting Lists | 1 | 2016 | 55 | 0.130 |
Why?
| Inflammation | 3 | 2012 | 641 | 0.130 |
Why?
| Blood Platelets | 1 | 2018 | 259 | 0.130 |
Why?
| Ultrasonography | 2 | 2022 | 430 | 0.130 |
Why?
| Chromosome Aberrations | 1 | 2017 | 297 | 0.120 |
Why?
| Signal Transduction | 1 | 2002 | 1671 | 0.120 |
Why?
| Drug Administration Schedule | 3 | 2012 | 374 | 0.120 |
Why?
| Patient Selection | 1 | 2016 | 259 | 0.120 |
Why?
| Cardiomyopathy, Dilated | 1 | 2015 | 40 | 0.120 |
Why?
| Fibrinogen | 1 | 2015 | 34 | 0.120 |
Why?
| Patient Care Planning | 1 | 2015 | 68 | 0.120 |
Why?
| Resuscitation | 1 | 2015 | 71 | 0.120 |
Why?
| Clavulanic Acids | 1 | 2014 | 8 | 0.120 |
Why?
| Ticarcillin | 1 | 2014 | 8 | 0.120 |
Why?
| Nerve Growth Factors | 2 | 2005 | 28 | 0.110 |
Why?
| Sternotomy | 1 | 2014 | 7 | 0.110 |
Why?
| Erythrocyte Transfusion | 1 | 2014 | 52 | 0.110 |
Why?
| Heart Septal Defects | 1 | 2014 | 14 | 0.110 |
Why?
| Factor Xa | 1 | 2014 | 7 | 0.110 |
Why?
| Peritoneal Dialysis | 2 | 2012 | 33 | 0.110 |
Why?
| Disease Progression | 2 | 2018 | 871 | 0.110 |
Why?
| Autopsy | 1 | 2014 | 48 | 0.110 |
Why?
| Antithrombin III | 1 | 2014 | 13 | 0.110 |
Why?
| Adrenal Glands | 1 | 2014 | 39 | 0.110 |
Why?
| Blood Coagulation Disorders | 1 | 2014 | 40 | 0.110 |
Why?
| Antithrombins | 1 | 2014 | 19 | 0.110 |
Why?
| Healthcare Disparities | 1 | 2017 | 299 | 0.110 |
Why?
| Tumor Suppressor Proteins | 2 | 2005 | 130 | 0.110 |
Why?
| Age Factors | 3 | 2017 | 1132 | 0.110 |
Why?
| Purines | 1 | 2013 | 34 | 0.110 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2015 | 203 | 0.100 |
Why?
| Heparin Antagonists | 1 | 2013 | 7 | 0.100 |
Why?
| Protamines | 1 | 2013 | 8 | 0.100 |
Why?
| Hernia, Diaphragmatic | 1 | 2013 | 22 | 0.100 |
Why?
| Adult | 5 | 2022 | 14161 | 0.100 |
Why?
| Aged | 4 | 2017 | 10121 | 0.100 |
Why?
| Thrombelastography | 1 | 2013 | 26 | 0.100 |
Why?
| Comorbidity | 2 | 2014 | 625 | 0.100 |
Why?
| Interleukin-3 | 1 | 2012 | 12 | 0.100 |
Why?
| Organizational Objectives | 1 | 2012 | 35 | 0.100 |
Why?
| Calcitonin Gene-Related Peptide | 1 | 2012 | 24 | 0.100 |
Why?
| Hip | 1 | 2012 | 23 | 0.100 |
Why?
| Protein Precursors | 1 | 2012 | 42 | 0.100 |
Why?
| Aircraft | 1 | 2012 | 8 | 0.100 |
Why?
| Calcitonin | 1 | 2012 | 30 | 0.100 |
Why?
| Hemorrhage | 1 | 2014 | 209 | 0.100 |
Why?
| Pulsatile Flow | 1 | 2012 | 18 | 0.100 |
Why?
| Rotation | 1 | 2012 | 44 | 0.100 |
Why?
| Professional-Family Relations | 1 | 2012 | 44 | 0.100 |
Why?
| Models, Organizational | 1 | 2012 | 58 | 0.100 |
Why?
| Treatment Failure | 1 | 2012 | 122 | 0.100 |
Why?
| Interdisciplinary Communication | 1 | 2012 | 57 | 0.100 |
Why?
| Vascular Resistance | 1 | 2012 | 51 | 0.100 |
Why?
| Patient Positioning | 1 | 2012 | 32 | 0.100 |
Why?
| Interleukin-8 | 1 | 2012 | 86 | 0.090 |
Why?
| Premedication | 1 | 2011 | 18 | 0.090 |
Why?
| Body Height | 1 | 2012 | 66 | 0.090 |
Why?
| Tertiary Care Centers | 1 | 2012 | 85 | 0.090 |
Why?
| Fluconazole | 1 | 2011 | 34 | 0.090 |
Why?
| Interleukin-10 | 1 | 2012 | 84 | 0.090 |
Why?
| Regional Blood Flow | 1 | 2012 | 109 | 0.090 |
Why?
| Blood Flow Velocity | 1 | 2012 | 95 | 0.090 |
Why?
| Septal Occluder Device | 1 | 2012 | 36 | 0.090 |
Why?
| Health Care Surveys | 1 | 2012 | 177 | 0.090 |
Why?
| Ketamine | 1 | 2012 | 59 | 0.090 |
Why?
| Infarction, Middle Cerebral Artery | 1 | 2011 | 40 | 0.090 |
Why?
| Heart Septal Defects, Ventricular | 1 | 2012 | 45 | 0.090 |
Why?
| Hemolysis | 1 | 2011 | 28 | 0.090 |
Why?
| Combined Modality Therapy | 1 | 2013 | 639 | 0.090 |
Why?
| Azygos Vein | 1 | 2011 | 11 | 0.090 |
Why?
| Tomography, X-Ray Computed | 2 | 2010 | 1165 | 0.090 |
Why?
| Neuroprotective Agents | 1 | 2012 | 101 | 0.090 |
Why?
| Thrombosis | 1 | 2014 | 253 | 0.090 |
Why?
| Cross Infection | 1 | 2011 | 93 | 0.090 |
Why?
| Comprehension | 1 | 2012 | 113 | 0.090 |
Why?
| Aortic Stenosis, Supravalvular | 1 | 2010 | 9 | 0.090 |
Why?
| Tissue Plasminogen Activator | 1 | 2011 | 109 | 0.090 |
Why?
| Thrombolytic Therapy | 1 | 2011 | 110 | 0.090 |
Why?
| Adrenal Cortex Function Tests | 1 | 2010 | 5 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 166 | 0.090 |
Why?
| Fibrinolytic Agents | 1 | 2011 | 128 | 0.090 |
Why?
| Adrenocorticotropic Hormone | 1 | 2010 | 30 | 0.090 |
Why?
| Interleukin-6 | 1 | 2012 | 278 | 0.090 |
Why?
| Catheterization | 2 | 2011 | 96 | 0.090 |
Why?
| Mycoses | 1 | 2011 | 152 | 0.090 |
Why?
| Brain Injuries | 1 | 2012 | 159 | 0.090 |
Why?
| Respiratory Tract Infections | 1 | 2011 | 87 | 0.090 |
Why?
| Boston | 1 | 2010 | 13 | 0.080 |
Why?
| Echocardiography | 2 | 2011 | 415 | 0.080 |
Why?
| Patient Care Team | 1 | 2012 | 272 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2012 | 399 | 0.080 |
Why?
| Feasibility Studies | 1 | 2012 | 406 | 0.080 |
Why?
| Hydrocortisone | 1 | 2010 | 111 | 0.080 |
Why?
| Diagnosis, Differential | 2 | 2004 | 1046 | 0.080 |
Why?
| Lactates | 1 | 2010 | 31 | 0.080 |
Why?
| Myocardial Infarction | 1 | 2014 | 412 | 0.080 |
Why?
| Inpatients | 1 | 2011 | 205 | 0.080 |
Why?
| Regression Analysis | 4 | 2013 | 401 | 0.080 |
Why?
| Nutritional Support | 1 | 2010 | 35 | 0.080 |
Why?
| Chronic Disease | 1 | 2012 | 586 | 0.080 |
Why?
| Lymphopenia | 1 | 2009 | 18 | 0.080 |
Why?
| Pulmonary Ventilation | 1 | 2009 | 12 | 0.080 |
Why?
| Pulmonary Gas Exchange | 1 | 2009 | 22 | 0.080 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2010 | 96 | 0.080 |
Why?
| Nutritional Status | 1 | 2010 | 137 | 0.080 |
Why?
| Alanine Transaminase | 1 | 2009 | 122 | 0.080 |
Why?
| Infant, Premature | 1 | 2012 | 333 | 0.080 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1031 | 0.080 |
Why?
| Substance Withdrawal Syndrome | 1 | 2010 | 168 | 0.080 |
Why?
| Antifungal Agents | 1 | 2011 | 347 | 0.080 |
Why?
| Attitude of Health Personnel | 1 | 2012 | 360 | 0.080 |
Why?
| Lactic Acid | 1 | 2009 | 78 | 0.080 |
Why?
| Analysis of Variance | 1 | 2010 | 554 | 0.080 |
Why?
| Reference Values | 1 | 2009 | 313 | 0.080 |
Why?
| Endocarditis, Bacterial | 1 | 2009 | 43 | 0.080 |
Why?
| Stroke | 1 | 2013 | 512 | 0.070 |
Why?
| Sex Factors | 1 | 2010 | 727 | 0.070 |
Why?
| Neutrophils | 1 | 2009 | 147 | 0.070 |
Why?
| Recombinant Proteins | 1 | 2009 | 483 | 0.070 |
Why?
| Pain | 1 | 2010 | 362 | 0.070 |
Why?
| Emergency Medical Services | 1 | 2008 | 114 | 0.070 |
Why?
| Age of Onset | 2 | 2018 | 110 | 0.070 |
Why?
| Abdomen | 1 | 2007 | 75 | 0.070 |
Why?
| Renal Dialysis | 2 | 2022 | 179 | 0.060 |
Why?
| Oximetry | 1 | 2007 | 66 | 0.060 |
Why?
| Receptors, Cell Surface | 2 | 2005 | 118 | 0.060 |
Why?
| Sensitivity and Specificity | 1 | 2008 | 891 | 0.060 |
Why?
| Cerebral Cortex | 1 | 2007 | 198 | 0.060 |
Why?
| Opioid-Related Disorders | 1 | 2010 | 400 | 0.060 |
Why?
| Leukocytes | 1 | 2005 | 66 | 0.060 |
Why?
| Cell Movement | 1 | 2005 | 268 | 0.060 |
Why?
| Analgesics, Opioid | 1 | 2010 | 590 | 0.060 |
Why?
| Pulmonary Surfactants | 1 | 2004 | 18 | 0.060 |
Why?
| India | 1 | 2004 | 68 | 0.060 |
Why?
| Posture | 1 | 2004 | 66 | 0.050 |
Why?
| Vasodilator Agents | 1 | 2004 | 96 | 0.050 |
Why?
| Endothelial Cells | 1 | 2005 | 262 | 0.050 |
Why?
| Intracranial Pressure | 1 | 2003 | 29 | 0.050 |
Why?
| Drosophila Proteins | 1 | 2003 | 25 | 0.050 |
Why?
| Dialysis | 1 | 2022 | 7 | 0.050 |
Why?
| Cell Adhesion Molecules | 1 | 2003 | 86 | 0.050 |
Why?
| Receptors, Immunologic | 1 | 2003 | 39 | 0.050 |
Why?
| Platelet-Derived Growth Factor | 1 | 2002 | 23 | 0.050 |
Why?
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2002 | 12 | 0.050 |
Why?
| Morphogenesis | 1 | 2002 | 18 | 0.050 |
Why?
| Sternum | 1 | 2022 | 12 | 0.050 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2002 | 137 | 0.050 |
Why?
| Intubation, Intratracheal | 1 | 2003 | 122 | 0.050 |
Why?
| Vasodilation | 1 | 2002 | 99 | 0.050 |
Why?
| Surgical Wound Infection | 1 | 2022 | 118 | 0.050 |
Why?
| Nerve Tissue Proteins | 1 | 2003 | 187 | 0.050 |
Why?
| Nitric Oxide | 1 | 2002 | 249 | 0.040 |
Why?
| Equipment Design | 2 | 2011 | 293 | 0.040 |
Why?
| Chi-Square Distribution | 2 | 2011 | 288 | 0.040 |
Why?
| Efficiency | 1 | 2018 | 32 | 0.040 |
Why?
| Staff Development | 1 | 2018 | 24 | 0.040 |
Why?
| Genetic Association Studies | 1 | 2018 | 122 | 0.040 |
Why?
| Social Responsibility | 1 | 2018 | 25 | 0.040 |
Why?
| Job Satisfaction | 1 | 2018 | 33 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1105 | 0.040 |
Why?
| Burnout, Professional | 1 | 2018 | 55 | 0.030 |
Why?
| Leadership | 1 | 2018 | 103 | 0.030 |
Why?
| Self Efficacy | 1 | 2018 | 134 | 0.030 |
Why?
| Age Distribution | 1 | 2017 | 174 | 0.030 |
Why?
| Communication | 1 | 2018 | 257 | 0.030 |
Why?
| Animals | 4 | 2005 | 13505 | 0.030 |
Why?
| Phenotype | 1 | 2018 | 789 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 528 | 0.030 |
Why?
| National Institutes of Health (U.S.) | 1 | 2015 | 43 | 0.030 |
Why?
| Multiple Organ Failure | 1 | 2015 | 49 | 0.030 |
Why?
| Hematocrit | 1 | 2014 | 44 | 0.030 |
Why?
| Hospital Charges | 1 | 2014 | 46 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 582 | 0.030 |
Why?
| Case Management | 1 | 2013 | 43 | 0.020 |
Why?
| Intention to Treat Analysis | 1 | 2012 | 30 | 0.020 |
Why?
| Prosthesis Design | 1 | 2013 | 256 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2012 | 138 | 0.020 |
Why?
| Centrifugation | 1 | 2011 | 12 | 0.020 |
Why?
| Gastroenteritis | 1 | 2011 | 19 | 0.020 |
Why?
| Central Nervous System | 1 | 2012 | 76 | 0.020 |
Why?
| Ductus Arteriosus | 1 | 2011 | 10 | 0.020 |
Why?
| Linear Models | 1 | 2012 | 287 | 0.020 |
Why?
| Ambulances | 1 | 2011 | 8 | 0.020 |
Why?
| Blood Pressure Monitors | 1 | 2010 | 10 | 0.020 |
Why?
| Hemoglobins | 1 | 2011 | 112 | 0.020 |
Why?
| Blood Pressure Determination | 1 | 2010 | 42 | 0.020 |
Why?
| Single-Blind Method | 1 | 2010 | 116 | 0.020 |
Why?
| Radiography | 1 | 2011 | 470 | 0.020 |
Why?
| Tachyphylaxis | 1 | 2010 | 2 | 0.020 |
Why?
| Receptors, Opioid | 1 | 2010 | 17 | 0.020 |
Why?
| Double-Blind Method | 1 | 2012 | 713 | 0.020 |
Why?
| Models, Statistical | 1 | 2011 | 230 | 0.020 |
Why?
| Prealbumin | 1 | 2010 | 22 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2011 | 591 | 0.020 |
Why?
| Child Development | 1 | 2012 | 200 | 0.020 |
Why?
| Drug Tolerance | 1 | 2010 | 60 | 0.020 |
Why?
| Cardiology | 1 | 2011 | 97 | 0.020 |
Why?
| Nutritional Requirements | 1 | 2010 | 67 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2013 | 1378 | 0.020 |
Why?
| Mice | 3 | 2005 | 5949 | 0.020 |
Why?
| Cytokines | 1 | 2012 | 623 | 0.020 |
Why?
| Anesthesia, General | 1 | 2010 | 99 | 0.020 |
Why?
| Intraoperative Complications | 1 | 2010 | 112 | 0.020 |
Why?
| Emergency Service, Hospital | 1 | 2011 | 522 | 0.020 |
Why?
| Neurons | 1 | 2010 | 418 | 0.020 |
Why?
| Dietary Supplements | 1 | 2010 | 465 | 0.020 |
Why?
| Chemotaxis | 1 | 2005 | 21 | 0.020 |
Why?
| Superoxides | 1 | 2005 | 46 | 0.020 |
Why?
| DNA Primers | 1 | 2005 | 208 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2012 | 1546 | 0.010 |
Why?
| Blotting, Western | 1 | 2005 | 590 | 0.010 |
Why?
| Pulmonary Surfactant-Associated Protein B | 1 | 2003 | 4 | 0.010 |
Why?
| Cells, Cultured | 1 | 2005 | 1567 | 0.010 |
Why?
| Middle Aged | 1 | 2017 | 13028 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2003 | 979 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2005 | 1884 | 0.010 |
Why?
|
|
Prodhan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|